. Ubiquitination is typically considered a post-translational modification of lysine residues, as there are no known human E3 ligases with non-lysine activity. Here we perform activity-based protein profiling of HECT or RBR-like E3 ligases and identify the neuron-associated E3 ligase MYCBP2 (also known as PHR1) as the apparent single member of a class of RING-linked E3 ligase with esterification activity and intrinsic selectivity for threonine over serine. MYCBP2 contains two essential catalytic cysteine residues that relay ubiquitin to its substrate via thioester intermediates. Crystallographic characterization of this class of E3 ligase, which we designate RING-Cys-relay (RCR), provides insights into its mechanism and threonine selectivity. These findings implicate non-lysine ubiquitination in cellular regulation of higher eukaryotes and suggest that E3 enzymes have an unappreciated mechanistic diversity.
Biotin-tagged ABPs enable parallelized massspectrometry-based HECT/RBR-like E3 profiling. The wavy bond represents triazole linkage to a truncated ubiquitin molecule (as described 7 ; Extended Data Fig. 1 and Methods). c, Spectral counts obtained from ABP-profiled oligomycin and antimycin A-treated SH-SY5Y neuroblastoma cells for proteins currently annotated as E3 or E1. The asterisk highlights the RBR E3 ligase Parkin (PRKN2), which is not detected when oligomycin and antimycin A treatment is withheld (Extended Data Fig. 2c, d ). d, Total number of HECT, RBR and RING E3s detected with the different probes. As the mutations introduced into control probes ABP3 and ABP4 are likely to impair rather than abolish E3 labelling, proteins with less than half the number of spectral counts of those obtained with their parental probe (ABP1 and ABP2, respectively) were not included in the plot. e, Number of E3 ligases detected using ABP1 and ABP2.
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HECT/RBR E3 ligases by this method, but unexpectedly, 33 RING E3 ligases, which lack HECT or RBR ancillary domains, were also enriched ( Fig. 1c-e) . To explore the possibility that previously undiscovered RING-linked E3 ligases were being labelled, we focused on MYCBP2 (Myc-binding protein 2), also known as PHR1 (PAM/Highwire/Rpm-1) (Fig. 1c) . MYCBP2 is a large, 0.5-MDa neuron-associated protein, which contains a C-terminal RING domain ( Fig. 2a) and is involved in a range of cellular processes including regulation of nervous system development and axon degeneration [10] [11] [12] . MYCBP2(cat), a recombinant C-terminal version of MYCBP2 encompassing the RING domain (residues 4378-4640; Fig. 2a ) and an uncharacterized C-terminal cysteine-rich region underwent robust ABP labelling with an efficiency comparable to that of E3 ligases known to demonstrate transthiolation activity 7,13 (Extended Data Fig. 3a) . To map the putative catalytic cysteine, we used a combination of ABPbased profiling and ABP-crosslinking mass spectrometry 7 (Fig. 2b , Extended Data Fig. 3b, c ; full gels and blots in Supplementary Fig. 1 ). The results of these experiments supported the hypothesis that C4520 is a putative catalytic residue. We next assayed wild-type E3 ligase activity, but were unable to detect autoubiquitination or free ubiquitin chain formation. However, we observed rapid E3-dependent discharge of ubiquitin from E2-Ub, suggesting the presence of an unknown smallmolecule nucleophilic acceptor (Fig. 2c) . Liquid chromatographymass spectrometry (LC-MS) analysis revealed that ubiquitin was being quantitatively converted into two species with masses corresponding to condensation products with tris(hydroxymethyl)aminomethane (Tris) and glycerol (8,639 Da and 8,668 Da, respectively), both of which were present in our assay buffer at routinely employed concentrations of 50 mM and around 65 mM, respectively. Owing to the common hydroxy functionality within these nucleophiles, MYCBP2 appeared to show esterification activity (Extended Data Fig. 4a , b); this activity was found to be dependent on C4520, consistent with it forming a thioester-linked E3-Ub intermediate 4, 5 (Fig. 2c ). Unexpectedly, a MYCBP2(C4572S) mutant retained activity while also forming a discrete mono-ubiquitin adduct that was resistant to thiolysis but was reversible after base treatment 5 (Fig. 2c, d , Extended Data Fig. 4c ). One possible explanation for this was that the mutant S4572 residue contributed to catalysis by forming an additional and less transient (oxy)ester-linked intermediate between ubiquitin and S4572 that retained the ability to modify substrate. We hypothesized that C4520 and C4572 are both catalytic residues that function in tandem by relaying ubiquitin from one cysteine to the other through an intramolecular transthiolation reaction. To test this relay mechanism, we carried out gel-based thioester-ester trapping assays 14 (Fig. 2e , Extended Data Fig. 4d ) and observed a thiol-sensitive ubiquitin adduct on wildtype MYCBP2(cat), which was not observed with the C4520S mutant (Fig. 2e) . Consistent with the earlier experiments (Fig. 2c) , C4572S underwent adduct formation that was thiol-resistant but base-labile (Fig. 2e) . Thus, if a transient thioester intermediate was being formed between ubiquitin and C4520, an unreactive C4572A mutant should stabilize it. Indeed, thiol-sensitive adduct formation was increased on a C4572A mutant relative to the wild type and was presumably linked via a thioester bond (Fig. 2e) . Adduct formation was not detected with a C4520A/C4572S double mutant, consistent with ubiquitin being linked to the C4520 residue (Fig. 2e) . In the absence of a direct demonstration of Cys-to-Cys ubiquitin transfer, we cannot formally exclude other possibilities. However, the existing data are consistent with the essential cysteines functioning in a relay mechanism. Mutational analysis and size exclusion chromatography-multi-angle light scattering (SEC-MALS) of MYCBP2(cat) (Extended Data Fig. 4e, f) suggests that the proposed relay mechanism requires that both essential cysteines are in the same molecule, consistent with an intramolecular-cis-relay mechanism.
In light of the observed esterification activity, we attempted to identify the amino acid substrate of MYCBP2 by screening a panel of amino acids 5 , and found that discharge activity was markedly enhanced with threonine. Product formation was dependent on C4520 (Fig. 3a, b , Extended Data Fig. 5a-d) . Mass-spectrometry-based quantification indicated approximately tenfold enhanced selectivity for threonine over serine (Extended Data Fig. 5e ). Although we observed a low level of lysine modification, this was independent of MYCBP2(cat) 5 . A threefold selectivity for threonine was also maintained in a peptide context (Fig. 3c, Extended Data Fig. 5f-h) . Furthermore, basal ubiquitination of a lysine peptide was partially inhibited in the presence of MYCBP2(cat), underscoring its lack of activity towards lysine (Fig. 3c) . Taken together, our experiments revealed that MYCBP2 is a member of a novel class of E3 ligase that operates via two essential cysteines, promotes ubiquitin modification of hydroxyl groups, and preferentially esterifies threonine over serine with ubiquitin. As MYCBP2 uses a novel mechanism, we termed it a RING-Cys-relay (RCR) E3 ligase. We measured the catalytic efficiency of the MYCBP2-threonine-esterification activity and found that it had an intermediate value between those of well-characterized HECT (UBE3C) and RBR (HHARI) E3 lysine aminolysis activity 5,15 (Extended Data Fig. 5i-k) . E2 mutational analysis 5, [16] [17] [18] [19] provided further support for MYCBP2(cat) being a member of a novel class of E3 ligase (Extended Data Fig. 6a, b and Methods). We tested 17 E2 conjugating enzymes to identify functional E2 partners, but only UBE2D1, UBE2D3 and UBE2E1 exhibited robust activity (Extended Data Fig. 6c ). MYCBP2 promotes Wallerian axon degeneration through destabilization of nicotinamide mononucleotide adenyltransferase (NMNAT2) 20 . We next tested whether MYCBP2(cat) can ubiquitinate NMNAT2 by esterification in vitro (Fig. 3d) . Despite containing 13 lysine residues, NMNAT2 underwent hydroxide-labile but . c, Multiple-turnover E2 discharge assay onto hydroxy nucleophiles (Tris and glycerol) present in the reaction buffer. BME, 2-mercaptoethanol in gel loading buffer; WT, wild-type. d, The ubiquitin adduct on MYCBP2(C4572S) is base-labile (0.14 N NaOH), indicative of the formation of an engineered (oxy)ester linkage between ubiquitin and S4572 on MYCBP2. e, SDS-PAGE thioester-ester trapping assay, tracking Cy3B-labelled ubiquitin. All biochemical data were consistent across three biological replicates with the exception of the mass spectrometry experiment which was carried out once.
Letter reSeArCH thiol-resistant ubiquitination, demonstrating that MYCBP2 can target hydroxy residues within one of its putative substrates 20 . Cellular substrate recognition is mediated by a Skp1-Fbxo45 substrate receptor co-complex that binds to a site approximately 1,940 residues N-terminal to the MYCBP2(cat) region 21 (Fig. 2a) . NMNAT2 also undergoes palmitoylation and rapid axonal transport 22 , making reconstitution and cellular study of its ubiquitination extremely challenging. However, to establish whether MYCBP2(cat) retains non-lysine activity in cells, we investigated autoubiquitination of MYCBP2(cat) after transient transfection into HEK 293 cells. Base-labile (but thiol-resistant) ubiquitination was observed that was dependent on C4520 (Fig. 3e) . This demonstrates that MYCBP2 can retain specificity for hydroxy amino acids in cells and that this activity remains dependent on the upstream catalytic residue that is implicated in the ubiquitin relay mechanism.
To further validate the RCR model and the serine and threonine activity, we crystallized MYCBP2(cat) (residues 4378-4640) and solved the crystal structure to a resolution of 1.75 Å (Extended Data  Table 1 and Extended Data Fig. 7a-c) . Residues 4388-4441 at the N terminus correspond to the predicted cross-brace C3H2C3 RING domain (Fig. 4a, Extended Data Fig. 7d ). Following the RING domain is a long α-helix (4447-4474) that leads into a small helix-turn-helix motif (residues 4475-4500) (Fig. 4a, Extended Data Fig. 7e) , and further C-terminal is a globular domain (residues 4501-4638) that binds four Zn ions (Fig. 4b, Extended Data Fig. 7f, g ). Since this domain also contains the two essential catalytic residues, we designate it the tandem cysteine domain. Between the βA2 strand and helix 3 10 A is an unstructured region (4519-4526) that projects out to the side of the core Zn-binding fold. The upstream C4520 residue resides within this unstructured region, which, together with flanking residues, forms a mobile region that we term the mediator loop. The configuration of Zn coordination (C5HC7HC2) in the tandem cysteine domain is semi-contiguous and does not adopt cross-brace architecture (Extended Data Fig. 7f ).
Crystal packing revealed that T4380, within the N terminus of a symmetry-related MYCBP2(cat) molecule (T4380(sym)), is located proximal to the esterification site where it forms a number of substrate-like interactions (Fig. 5a, b) . First, the β-hydroxy group of T4380(sym) complements E4534 and H4583 and forms a potential triad (Fig. 5a ). Thus the β-oxygen atom of T4380(sym) appears to be primed for deprotonation and nucleophilic attack. The C terminus of ubiquitin, when thioester-linked to C4572, is a catalytically productive electrophilic centre. Even though this ubiquitin molecule is absent from our structure, the sulfur atom in C4572 is 3.8 Å away from the β-oxygen atom of T4380(sym). Therefore, the structure appears to accurately reflect a catalytic intermediate that is poised to undergo threonine ubiquitination by esterification of its β-hydroxy group (Fig. 5a ). Furthermore, a sub-cluster of phenylalanine residues (F4573, F4578 and F4586), proximal to the β-methyl group of T4380(sym) (Fig. 5a, b) , forms a well-defined hydrophobic pocket that the β-methyl group of T4380(sym) docks into, and seems to be a positive determinant of selectivity for the threonine side chain. The proposed roles of these residues were validated in threonine discharge assays (Fig. 5c) . A H4583N mutation abolished activity consistent with a role for this residue as a general base. The H4583N mutant also underwent enhanced, thiol-sensitive Letter reSeArCH ubiquitin adduct formation in accordance with the anticipated defect in rendering substrate nucleophiles reactive towards the C4572 thioester (Extended Data Fig. 8a ). Conservative perturbation of the phenylalanine cluster also markedly reduced threonine discharge activity (Fig. 5c ). However, perturbation of E4534 did not reduce activity; consequently, its precise role remains unclear.
Conservation of RING-domain binding to E2 [16] [17] [18] 23 permitted the modelling of an E2-RCR E3 ligase complex that was geometrically compatible with transthiolation between E2-Ub and C4520 in MYCBP2(cat) (Fig. 5d, Extended Data Fig. 8b ). To simulate the conformation required for subsequent ubiquitin relay to C4572, we modelled the missing mediator-loop residues with a Gly-Gly dipeptide thioester linked to C4520, representative of the C terminus of ubiquitin that would be transferred via transthiolation with E2-Ub if our relay model was valid (Extended Data Fig. 8c-e) . Consistent with this mechanism, the carbonyl-carbon of the ubiquitin thioester could be positioned in the proximity (around 3 Å) of the C4572 sulfhydryl sulfur atom. To adopt this conformation, minor twisting of a Gly-Gly motif (residues 4515-4516) at the tip of the βA2 strand was necessary. Clashes were observed between mediator-loop residues further C-terminal and R4533, E4534, N4580, H4583 and D4584, but these could largely be relieved by rotations of their side chains into available space (Extended Data Fig. 8d ). As ordered loop residues 4527-4531 required a substantial displacement to generate the model, we speculate that the mobile mediator loop region would span residues 4515-4531. As C4520, which resides within this mobile structural element, needs to be engaged by the E2 active site 24 this might account for the uncharacterized E2 residue requirements. The inability to render the S4520 mutant catalytic in earlier experiments might be explained by its dynamic nature and the absence of a general base that could suppress the acid dissociation constant (pK a ) of the otherwise fully protonated S4520 side chain. Hence, native catalytic activity at C4520 is likely to arise from the intrinsic nucleophilicity of sulfhydryl groups (Extended Data Fig. 8a ).
Although non-lysine ubiquitination has been reported [25] [26] [27] , an E3 ligase that preferentially carries out this function in humans has remained elusive. Our characterization of the novel RCR E3 ligase in MYCBP2 suggests that ubiquitination by esterification is intrinsic to higher eukaryotes, and may be a regulator of synapse development and axon degeneration. Furthermore, non-protein ubiquitin substrates (such as lipids or carbohydrates) have not been reported, but considering the high esterification activity of MYCBP2 towards small-molecule hydroxy compounds, they remain a possibility. It is not immediately clear why the proposed relay (Fig. 6a) mechanism would have evolved. However, transthiolation is a cofactor-independent process that provides an efficient means of shuttling ubiquitin throughout the ubiquitin system 1 . We speculate that, on steric grounds, direct E2-E3 transthiolation with the structurally rigid and highly conserved E2 ubiquitin-conjugating domain (Ubc) 28 , and serine and threonine activity, are mutually exclusive at the esterification site; evolution of the mediator loop addresses this compatibility issue. Bioinformatic analysis revealed that orthologues of MYCBP2 are found in virtually all HOIP in complex with E2 (PDB ID: 5EDV; the ubiquitin linked to E2 has been omitted owing to a direct clash with the tandem cysteine domain 18 ) allows modelling of the E2 into our structure (grey cartoon representation). e, Modelling of the proposed ubiquitin relay mechanism. Tandem-cysteine-domain residues and mediator-loop residues from the experimentally determined structure are shown in orange and dark brown, respectively; tandem-cysteine-domain and mediator-loop residues from the model are shown in light orange and mauve, respectively. The modelled E2 is shown as grey cartoon, whereas ubiquitin residues (G75-G76) are shown in blue ball and stick representation. Table 2 ). Stabilization of NMNAT2 through inhibition of MYCBP2 is a promising therapeutic strategy for mitigating neuron damage after injury and administration of chemotherapeutics 10, 29, 30 , and for slowing the progression of a range of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease 29 . The delineation of this apparent ubiquitin relay mechanism and the structural characterization of the molecular machinery responsible suggests new potential targets for treating a range of neurological conditions.
animals, but human homologues are unlikely to exist (Extended Data
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0026-1. 18 
Letter reSeArCH

MEthodS
General materials. All DNA constructs were verified by DNA sequencing (Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee). DNA for bacterial protein expression was transformed into Escherichia coli BL21-DE3 (Merck). All cDNA plasmids and antibodies generated for this study are available on request through our reagents website (https://mrcppureagents. dundee.ac.uk/). All solvents and reagents were purchased from Sigma-Aldrich or VWR unless otherwise stated. Biotin-functionalized ABP preparation. Ubiquitin with a GCSSG N-terminal extension was expressed from plasmid pTXB1-UbΔ74-76-T3C
7 . An equivalent plasmid encoding ubiquitin residues 1-74 (pTXB1-UbΔ75-76-T3C) was also created. Ubiquitin thioesters were obtained as described previously, generating cysteine tagged Cys-Ub 1-73 -SR and Cys-Ub 1-74 -SR, respectively 7 , where SR is SCH 2 CH 2 SO 3 H. The extended Ub 1-74 was included as it retains Arg74, which forms a favourable electrostatic interaction with the RBR E3 HOIP 31 . Cys-Ub 1-73 -SR (30 mg) was reconstituted by the addition of DMSO (116 μl) followed by H 2 O (456 μl). An aqueous stock solution (48 mM) of EZ-link Iodoacetyl-PEG2-biotin (Thermofisher) was prepared and 200 μl was added to the Cys-Ub 1-73 -SR solution (580 μl) followed by the addition of 900 μl degassed buffer (50 mM Na 2 HPO 4 pH 7.5, 150 mM NaCl). The reaction was incubated at 23 °C for 1 h and monitored by LC-MS. The protein (biotin-Ub 1-73 -SR) was then further purified by semi-preparative reversed-phase high-pressure liquid chromatography (RP-HPLC) (Column: BioBasic-4; part number: 72305-259270). A gradient of 20% buffer A to 50% buffer B was applied at a flow rate of 10 ml min −1 over 60 min (buffer A, 0.1% TFA in H 2 O; buffer B, 0.1% TFA in acetonitrile). The above procedure was repeated to generate Biotin-Ub 1-74 -SR. HPLC fractions containing biotin-Ub 1-7× -SR were pooled and lyophilized (yield: biotin-Ub 1-73 -SR, 75-85%; biotin-Ub 1-74 -SR, 40-50%) (Extended Data Fig. 1a, d ). Biotin-tagged ABPs containing thioacrylamide warheads were then prepared as previously described 7 , using the E2-recognition elements UBE2D2*, UBE2D2*(F62A), UBE2L3* and UBE2L3*(F63A), resulting in ABP1, ABP3, ABP2 and ABP4, respectively (Extended Data Fig. 1b, c, e, f) ; the asterisk denotes E2 in which non-catalytic Cys residues were mutated to Ser. ABPs based on UBE2D2* and UBE2D3* bearing hexahistidine reporter tags and thioacrylamide warheads (Extended Data Fig. 3a) were also prepared, yielding ABP5 and ABP6, respectively. Cell culture and lysis. SH-SY5Y cells were cultured and lysed as previously described 7 . HEK293 cells were cultured (37 °C, 5% CO 2 ) in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 2.0 mM l-glutamine and antibiotics (100 units ml −1 penicillin, 0.1 mg ml −1 streptomycin). Cell transfections were performed using polyethylenimine (Polysciences) according to the manufacturer's instructions. MG-132 (50 μM) was added to cells two hours before lysis. Cells were rinsed with ice-cold PBS and extracted in lysis buffer (1% NP-40, 50 mM Tris-HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 0.27 M sucrose, 10 mM sodium 2-glycerophosphate, 0.2 mM phenylmethanesulfonyl fluoride (PMSF), 1.0 mM benzamidine, 1 mM sodium orthovanadate, 50 mM sodium fluoride and 5 mM sodium pyrophosphate, 50 mM iodoacetamide and cOmplete EDTA-free protease inhibitor cocktail (Roche)). Lysates were then clarified by centrifugation at 4 °C for 30 min at 21,100 g. Supernatants (total cell extracts) were collected and protein concentration was determined by Bradford assay. For the base-lability test, indicated cell lysates were further incubated with 0.5 M hydroxylamine, pH 9.0 at 37 °C for 30 min. Mycoplasma tests were carried out in accordance with departmental protocols and the results were negative. Immunoblotting. Samples were mixed with NuPAGE LDS sample buffer (Thermofisher) without boiling, and resolved by SDS-PAGE (4-12% NuPage gel, Thermofisher) with MOPS or MES running buffer and transferred on to 0.45-μm nitrocellulose membranes (GE Life Sciences). Membranes were blocked with PBS-T buffer (PBS, 0.1% Tween-20) containing 5% (w/v) non-fat dried skimmed milk powder (PBS-TM) at room temperature for 1 h. Membranes were subsequently probed with the indicated antibodies in PBS-T containing 5% (w/v) bovine serum albumin (BSA) overnight at 4 °C. Detection was performed using horseradish peroxidase (HRP)-conjugated secondary antibodies in PBS-TM for 1 h at 23 °C. ECL western blotting detection reagent (GE Life Sciences) was used for visualization according to the manufacturer's protocol. Antibodies. His-tagged species were probed with 1:10,000 anti-His primary antibody (Clontech, #631212). Alpha tubulin (1E4C11) mouse mAb (Proteintech) was used at 1:10,000 dilution. The MYCBP2 antibody was raised in sheep inoculated with residues 4,378-4,640 of human MYCBP2 by MRC PPU Reagents and Services. Anti-MYCBP2 from the second bleed of SA357 was affinity-purified against the antigen and used at 0.5 μg ml Activity-based proteomic profiling of SH-SY5Y cells. SH-SY5Y total cell lysate (4.5 mg, 550 μl) was mixed with ABPs 1, 2, 3 or 4 (3 μM) and incubated at 30 °C for 4 h. To induce Parkin activation, cells were administered with oligomycin (5 μM) and antimycin A (10 μM) for 3 h. Control enrichments were also performed without probes. Extracts were mixed with 100 μl Pierce Streptavidin Plus UltraLink Resin (ThermoFisher Scientific) and diluted with 6% SDS solution (20 μl) to a final concentration of 0.2%. Samples were incubated for 4 h at 4 °C and resin washed (2 ml 0.2% SDS in PBS; 2 ml PBS; 1 ml 4 M urea in PBS; 2 ml PBS) and then resuspended in 190 μl Tris buffer (50 mM Tris pH 8, 1.5 M urea). Resin-bound proteins were reduced with TCEP (5 mM) for 30 min at 37 °C and then alkylated with iodoacetamide (10 mM) at 23 °C for 20 min. DTT (10 mM) was then added followed by washing with buffer (50 mM Tris pH 8, 1.5 M urea) to a final volume of 300 μl. Trypsin (2 μg) was then added and further incubated at 37 °C for 14 h. Trifluoroacetic acid was added to a final concentration of 0.1% and samples were desalted with a C18 MacroSpin column (The Nest Group). LC-MS/MS analysis was performed on an LTQ Orbitrap Velos instrument (Thermo Scientific) coupled to an Ultimate Nanoflow HPLC system (Dionex). A gradient running from 3% solvent B to 99% solvent B over 345 min was applied (solvent A, 0.1% formic acid and 3% DMSO in H 2 O; solvent B, 0.08% formic acid and 3% DMSO in 80% MeCN). Data processing. Raw files were searched against the Swiss-Prot database and a decoy database using the MASCOT server (Matrix Science). Trypsin specificity with up to three missed cleavages was applied. Cysteine carbamylation was set as a fixed modification and variable modifications were methione oxidation and dioxidation. A PERL script was used to extract the number of rank 1 peptides for each protein from the MASCOT search results and this figure was used as the number of spectral counts. A second PERL script filtered the data by searching the human swisspfam_v30 database using the E3 domain terms RING, HECT, IBR and zf-UBR. Manual curation was also carried out which involved the addition of E1 enzymes. Any proteins with fewer than three spectral counts and less than 14-fold spectral-count enrichment relative to control experiments in which probes were omitted from the list. Pairwise datasets were then plotted as column charts in Prism (GraphPad Software).
Cloning of MYCBP2(cat).
Human MYCBP2 (NM_015057.4) sequences were amplified from full-length Addgene plasmid no. 2570. Wild-type and mutant fragments were subcloned as BamHI-Not1 inserts into pGEX6P-1 (GE Life Sciences) for bacterial expression, or a modified version of pcDNA TM5/FRT/ TO (ThermoFisher) containing an N-terminal Myc tag for mammalian expression. UBE1 and E2 expression and purification. His 6 -UBE1 was expressed in Sf21 cells and purified via its tag as previously described 32 . Phosphate-buffered saline was used throughout the purification and hydroxy-containing compounds were avoided. UBE2D3 was expressed as an N-terminally His 6 -tagged protein in BL21 cells, purified over Ni-NTA-agarose and dialysed into 50 mM Na 2 HPO 4 pH 7.5, 150 mM NaCl, 0.5 mM TCEP. UBE2A was expressed as a GST fusion in E. coli and the GST tag was proteolytically removed. The other E2s were expressed as recombinant bacterial proteins and purified via their His tags and buffer exchanged by size exclusion chromatography into running buffer (50 mM Na 2 HPO 4 pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 0.015% Brij-35) using a Superdex 75 column (GE Life Sciences). Expression and purification of MYCBP2 and GST-MYCBP2. Wild-type and mutant GST-tagged MYCBP2(cat) were expressed at 16 °C overnight and purified with glutathione resin (Expedeon) using standard procedures. GST-tagged constructs were eluted with glutathione and untagged constructs were obtained by on-resin cleavage with rhinovirus 3 C protease. Proteins were buffer exchanged into storage buffer (50 mM Na 2 HPO 4 pH 7.5, 150 mM NaCl, 1.0 mM TCEP) and kept at −80 °C. Expression and purification of NMNAT2. NMNAT2 was expressed with a His 6 -SUMO tag in BL21(DE3) cells, induced with 0.1 mM IPTG and incubated for expression at 16 °C. The cells were collected and lysed in 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 0.2 mM EGTA, 20 mM imidazole, 20 mM l-arginine, 0.015% Brij-35, 1 mM leupeptin, 1 mM Pefabloc, 1 mM DTT using standard protocols and the protein was purified over Ni-NTA-agarose. The eluted protein was incubated with His-SENP1 protease during dialysis against PBS, 20 mM l-arginine, 1 mM DTT. The tag and protease were depleted against Ni-NTA-agarose and NMNAT2 was concentrated and subjected to chromatography on a Superdex 75 h 10/30 column into PBS, 20 mM l-arginine. Activity-based protein profiling of MYCBP2 cysteine mutants. The indicated MYCBP2 mutant was diluted into Tris buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl) to a final concentration of 3 μM. ABP6 was added (12 μM) and incubated with E3 ligase at 30 °C for 4 h. Reactions were quenched by the addition of 4 × LDS loading buffer (supplemented with ~680 mM 2-mercaptoethanol) and samples were resolved by SDS-PAGE (4-12% NuPage gel) followed by Coomassie staining or anti-His immunoblotting. Tryptic MS/MS sequencing of probe-labelled MYCBP2. Crosslinking mass spectrometry using ABP6 was carried out as previously described 7 . In summary, the Coomassie-stained SDS-PAGE band corresponding to ABP-labelled wildtype MYCBP2 was analysed by LC-MS/MS using an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific) coupled to an Ultimate Nanoflow HPLC system (Dionex). A gradient running from 0% solvent A to 60% solvent B over 120 min was applied (solvent A = 0.1% formic acid in H 2 O; solvent B = 0.08% formic acid in 80% MeCN). Fragment ions were generated by HCD and 1 + , 2 + and 3 + precursor ions were excluded. Raw data were searched using the pLink software 33 against UBE2D3* and MYCBP2 sequences with trypsin specificity (up to two missed cleavages). The error window for MS/MS fragment ion mass values was set to the software default of 20 p.p.m. A crosslinker monoisotopic mass of 306.1805 Da was manually added, which accounted for the theoretical mass difference associated with formation of a bis(thioether) between two Cys residues derived from ABP6, which was based on UBE2D3* and contained a thioacrylamide AVS warhead 7 . Tris-glycerol-mediated E2-discharge assay. Assays were carried out in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 5 mM MgCl 2 containing the indicated MYCBP2 mutant (15 μM), UBE1 (1.5 μM), UBE2D3 (15 μM), ubiquitin (37 μM) and ATP (10 mM). The reactions were incubated at 37 °C for 30 min. Reactions were terminated by the addition of 4 × LDS loading buffer (with and without ~680 mM 2-mercaptoethanol). A C4572S sample was further incubated with 0.14 N NaOH at 37 °C for 20 min and samples were resolved by SDS-PAGE (4-12% NuPage gel) and visualized by Coomassie staining. LC-MS analysis of nucleophile discharge assays. Reactions were prepared as described for the E2 discharge assay. After 30 min, the reaction was analysed using an Agilent 1200/6130 LC-MS system (Agilent Technologies) using a 10-75% gradient over 20 min (buffer A, H 2 O + 0.05% TFA; buffer B, acetonitrile + 0.04% TFA). Preparation of Cy3B-Ub. Ubiquitin bearing a TEV protease-cleavable N-terminal hexahistidine tag followed by an ACG motif was expressed in bacteria from a pET plasmid (R. Hay, University of Dundee). Protein was purified by Ni-affinity chromatography, cleaved from the tag with TEV protease then buffer exchanged into reaction buffer (50 mM HEPES, pH 7.5, 0.5 mM TCEP). Protein was concentrated to 2 mg ml −1 and 221 μl (50 nmol) of this was mixed with Cy3B-maleimide (150 nmol, GE Life Sciences) in a final volume of 300 μl and agitated for 2 h at 25 °C. Labelled protein was then further purified with a P2 Centri-Pure desalting column (EMP Biotech) with degassed buffer (50 mM Na 2 HPO 4 , 150 mM NaCl). MYCBP2 thioester-ester trapping assay. UBE1 (2 μM) was mixed with Cy3B-Ub (1 μM) in 40 mM Na 2 HPO 4 -HCl pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 5 mM MgCl 2 (Fig. 2e, lanes 1, 2) . The reaction was then initiated by the addition of ATP (5 mM) and incubated for 10 min at 25 °C. Samples (lanes 3, 4) were taken and combined with UBE2D3 (10 μM). After a further 10 min at 25 °C, samples (lanes 5, 6) were taken and combined with GST-MYCBP2(cat) (wild-type, C4520S, C4520A, C4572S, C4572A, C4520A/C4572S or C4520S/C4572A) (15 μM). The reactions were incubated at 25 °C for 30 s and terminated by the addition of 4 × LDS loading buffer (either non-reducing or reducing). For Ub-GST-MYCBP2(cat-C4572S) ester bond cleavage, 0.14 N NaOH was added after E3 reaction with E1 and E2 for 30 s and then further incubated at 37 °C for 20 min. The gel was then scanned with a Chemidoc Gel Imaging System (BioRad). Multiple-turnover amino acid and peptide panel discharge assays. Stock solutions (0.5 M) of amino acids were dissolved in Milli-Q water and pH was adjusted to ~8. Peptides with the sequence Ac-EGXGN-NH 2 (where X = K, S or T) were obtained from Bio-Synthesis. Stock peptide solutions (200 mM) were dissolved in Milli-Q water and pH was adjusted to ~8. An E2 (UBE2D3)-charging reaction was carried out in 40 mM Na 2 HPO 4 -HCl pH 8.0, 150 mM NaCl, 0.5 mM TCEP containing UBE1 (250-500 nM), UBE2D3 (20 μM), ubiquitin (50 μM) or Cy3B-Ub (25 μM), MgCl 2 (5 mM) and ATP (10 mM). The reaction was incubated at 37 °C for 15 min and then equilibrated to 23 °C for 3 min. An equivalent volume of nucleophile sample containing small molecule-peptide nucleophile (100 mM) and GST-MYCBP2 (10 μM) was then added and incubated at 23 °C. Samples were taken at the specified time points and analysed as described for Tris-glycerol-mediated E2 discharge assay.
Cy3B-Ub was visualized using a Chemidoc Gel Imaging System (Bio-Rad). LC-MS was carried out as described for Tris-glycerol discharge but amino acid substrate samples were quenched by the addition of 2:1 parts quenching solution (75% acetonitrile, 2% TFA) and peptide substrate samples were quenched by addition of 1:1 parts quenching solution. Multiple-turnover E2 discharge panel. E2s were screened for threonine discharge activity with GST-MYCBP2 cat as described for the amino acid panel. E2s were also incubated in the presence of threonine but in the absence of GST-MYCBP2 cat. These samples provided a reference to distinguish between intrinsic E2-Ub instability and E3-dependent discharge. Single-turnover E2 mutant discharge by in-gel fluorescence. E2 mutants 16, 17, [34] [35] [36] (10 μM) were charged with Cy3B-labelled ubiquitin (12.5 μM) in a final volume of 12 μl at 37 °C for 20 min then cooled at 23 °C for 3 min. E2 recharging was then blocked by the addition of MLN4924 derivative, compound 1 (25 μM) 37 , which inhibits E1, and then incubated for a further 15 min. The mixture was then mixed with 12 μl of GST-MYCBP2 cat (5 μM) and threonine (100 mM) and incubated at 23 °C for the specified time. Analysis was carried out as for multiple-turnover assays. To account for intrinsic E2-Ub instability the mean percentage discharge (n = 2) was calculated against a parallel incubation without E3. Data were plotted using Prism (GraphPad). Expression and purification of ARIH1 and UBE3C. ARIH1 (residues 1-394) (Dundee clone DU24260) was expressed as an N-terminally GST-tagged fusion protein in BL21 cells. UBE3C (residues 641-1,083) (Dundee Clone DU45301) was expressed as an N-terminally GST-tagged fusion protein in Sf21 cells using a baculovirus infection system. Calculation of observed rate constants for E3-substrate-dependent singleturnover E2-Ub discharge. UBE2D3 or UBE2L3 (5 μM) were charged with Cy3B-labelled ubiquitin (8 μM) in a final volume of 30 μl at 37 °C for 25 min and then incubated at 23 °C for 3 min. Single-turnover conditions for E2-Ub discharge were achieved by E1 inhibition with MLN4924 derivative, compound 1 (25 μM) and then incubated for a further 15 min. The mixture was then mixed with 30 μl of MYCBP2(cat) or ARIH1(1-394) (HHARI) or UBE3C(641-1083) (1 μM) and threonine (100 mM) and incubated at 23 °C for the specified time. Samples were quenched with non-reducing 4 × LDS loading buffer and resolved by SDS-PAGE (Bis-Tris 4-12%). The gel was then scanned with a Chemidoc Gel Imaging System (Bio-Rad) and subsequently Coomassie stained. E2-Ub signals were quantified using Fiji software. Observed rate constants were obtained by fitting reaction progress curves to a single exponential function using Prism (GraphPad). MYCBP2 crystallization. MYCBP2 was expressed as described for untagged protein. After protease cleavage of the tag the protein was further purified by size-exclusion chromatography using an ÄKTA FPLC system and a HiLoad 26/600 Superdex 75 pg column (GE Life Sciences). The running buffer consisted of 20 mM HEPES pH 7.4, 150 mM NaCl, 4 mM DTT. Combined fractions were concentrated to 10.4 mg ml −1
. Sparse matrix screening was carried out and bipyrimidal crystals were obtained from the Morpheus screen condition C1 (Molecular Dimensions). A subsequent optimization screen yielded multiple crystals (Buffer system 1 (MES/ imidazole) pH 6.7, 23.3 mM Na 2 HPO 4 , 23.3 mM (NH 4 ) 2 SO 4 , 23.3 mM NaNO 3 , 18% PEG500 MME, 9% PEG20000). A single crystal was soaked in mother liquor and further cryoprotected by supplementation with 5% PEG400 and frozen in liquid N 2 . Data were collected to 1.75 Å at the European Synchrotron Radiation Facility at Beamline ID23-1. Energy was set to the peak value of 9.669 keV (1.2823 Å), as determined by an absorption edge energy scan. A total of 360° were collected with an oscillation range of Ω = 0.1°. The phase problem was solved by locating six Zn 2+ sites in the anomalous signal and solvent flattening with the SHELX suite. An initial model was built by ARP/wARP 38 and subsequently optimized by manual building in COOT 39 and refinement with REFMAC5 40 , resulting in the final model with statistics as shown in Extended Data Fig. 7 . Final Ramachandran statistics were favoured: 95.55%, allowed: 3.24%, outliers: 1.21%. Size exclusion chromatography with multi-angle light scattering (SEC-MALS). SEC-MALS experiments were performed on an Ultimate 3000 HPLC system (Dionex) with an in-line miniDAWN TREOS MALS detector and Optilab T-rEX refractive index detector (Wyatt). In addition, the elution profile of the protein was also monitored by UV absorbance at 280 nm. A Superdex 75 10/300 GL column (GE Life Sciences) was used. Buffer conditions were 50 mM Na 2 HPO 4 pH 7.5, NaCl 150 mM, 1.0 mM TCEP and a flow rate of 0.3 ml min −1 was applied. Sample (50 μl, 5.5 mg ml −1 ) was loaded onto the column with a Dionex autosampler. Molar masses spanning elution peaks were calculated using ASTRA software v.6.0.0.108 (Wyatt). Mediator loop modelling. Mediator loop residues were built and geometry optimized within the Bioluminate Software (Schrödinger). Side chains were modified within COOT 39 and figures were generated with PyMOL (Schrödinger). Ramachandran analysis was carried with the RAMPAGE server 41 . NMNAT2 ubiquitination assay. NMNAT2 (5 μM) was mixed with E1 (500 nM), UBE2D3 (10 μM), MYCBP2(cat) (10 μM), ubiquitin (50 μM), ATP (10 mM) and made up with 10 × pH 7.5 buffer (40 mM Na 2 H 2 PO 4 pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 0.5 mM TCEP). The reactions were incubated at 37 °C for 1 h and terminated by the addition of 4 × LDS loading buffer (either non-reducing or reducing). For base-lability test, reactions were supplemented with 0.14 N NaOH and then further incubated at 37 °C for 20 min. Bioinformatic analysis. Proteins belonging to the RCR family were identified by generalized profile searches. Overall 671 such sequences were identified. The sequences were aligned by profile-guided alignment using the pftools package. For identifying representative sequences from various taxa, the Belvu program (Sanger Institute) was used to remove sequences with > 80% identity to other sequences. Truncated and misassembled proteins were removed manually, resulting in 130 representative tandem-cysteine-domain sequences. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. 
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Extended Data Fig. 2 | Activity-based proteomic profiling of  neuroblastoma SH-SY5Y cells. a-d , Parallel profiling of neuroblastoma SH-SY5Y cell extracts was carried out with ABPs 1-4. As an additional control, cells were left untreated or treated with inhibitors of oxidative phosphorylation, oligomycin and antimycin A, which enables activitydependent labelling of the RBR E3 Parkin 7 . ABP-labelled proteins were enriched against streptavidin resin followed by on-resin tryptic digestion. Obtained peptides were analysed by data-dependent LC-MS/MS. Recovered proteins were filtered against E3-associated PFAM domain terms (RING, HECT, IBR, zf-UBR) and proteins with fewer than three spectral counts were excluded. E3s that did not demonstrate more than 14-fold spectral count enrichment compared to control purifications, in which ABP was withheld, were also excluded. E1s yielded a strong signal, because they undergo transthiolation and are highly enriched by our ABPs. The number of spectral counts for the majority of HECT/RBR E3s was reduced by > 50% relative to their parental counterpart when the binding-defective control probes ABP3 and ABP4 were used (Fig. 1c) . The aggregate number of recovered HECT/RBR E3s from ABP1 and ABP2 was 33 (22 HECT and 11 RBR), representing around 80% of the currently annotated HECT/RBR E3s (Fig. 1d) . A subset of E3s remain permissive to control probes ABP3 and ABP4; we cannot establish whether this is because the respective E3s are labelled in an activity-independent manner or whether they are permissive to the F62A or F63A mutation.
Furthermore, ABP-dependent spectral count signals are not normalized against protein abundance. Therefore, we cannot deconvolute the effects of E3 activation stoichiometry from E3 abundance (that is, highly abundant E3s that are in a low-activation state could yield disproportionately high signals in our data). a, The number of spectral counts for the recovered E1 and E3 proteins plotted against protein ID for UBE2D2 ABP1 and its respective control probe UBE2D2(F62A) ABP3. MYCBP2 yields a high signal with ABP1, which is reduced by more than 50% with ABP3. A number of RING E3s that bind the ABP are also labelled, and for the majority of cases this is presumed to be mechanistically off-target labelling that is exacerbated by the high sensitivity of mass spectrometry-based detection. Another possibility is that hitherto undiscovered RING-linked E3s are being labelled. b, The number of spectral counts for the recovered E1 and E3 proteins plotted against protein ID for UBE2L3 ABP2 versus the respective control probe UBE2L3(F63A) ABP4. MYCBP2 is not detected with UBE2L3 ABP2 and ABP4. c, The number of spectral counts for E1 and E3 proteins obtained with ABP1 for untreated versus oligomycin and antimycin A-treated cells. d, The number of spectral counts for E1 and E3 proteins obtained with ABP2 for untreated versus oligomycin and antimycin A-treated cells. Parkin peptides were only recovered from cells treated with oligomycin and antimycin A, consistent with activitydependent Parkin labelling. Thus, for at least a subset of detected E3s, spectral counts correlate with E3 activity.
